Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan
Article first published online: 7 JUL 2009
© 2009 The Authors; Journal compilation © 2009 Japanese Psychogeriatric Society
Volume 9, Issue 2, pages 50–55, June 2009
How to Cite
NOZAWA, M., ICHIMIYA, Y., NOZAWA, E., UTUMI, Y., SUGIYAMA, H., MURAYAMA, N., ISEKI, E. and ARAI, H. (2009), Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Psychogeriatrics, 9: 50–55. doi: 10.1111/j.1479-8301.2009.00291.x
- Issue published online: 7 JUL 2009
- Article first published online: 7 JUL 2009
- Received 8 December 2008; accepted 9 March 2009.
- Alzheimer's disease;
- apolipoprotein E4;
- high oral dose
Background: Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer's disease.
Methods: We evaluated the efficacy and adverse effects of donepezil when the dose was increased to 10 mg/day in 61 Japanese patients with Alzheimer's disease. Cognitive function was evaluated using the Revised Hasegawa Dementia Scale and mini-mental state examination at the day before starting, and at 4, 8 and 24 weeks after starting donepezil 10 mg/day. The relationship with apolipoprotein E4 was also investigated.
Results: The Revised Hasegawa Dementia Scale and mini-mental state examination scores were not statistically significantly different at any time after starting donepezil 10 mg/day. It can be anticipated that donepezil 10 mg/day will especially inhibit deterioration of cognitive function in advanced Alzheimer's disease. The incidence of adverse events was 11.5%, lower than the rate of 40% or higher recorded during previous clinical trials.
Conclusions: The progression of cognitive dysfunction could be inhibited by increasing the dose of donepezil to 10 mg/day. It was suggested that longer-term treatment with 5 mg/day might lead to fewer adverse events when the dose is increased to 10 mg/day.